Overview

A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the long-term safety and efficacy of TAU-284 (Bepotastine besilate) in pediatric patients with perennial allergic rhinitis for 12 weeks administration.
Phase:
Phase 3
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation
Treatments:
Bepotastine besilate